Esat Quiz March 1- Cefi L Med Ref

10 Questions

Settings
Please wait...
March Quizzes & Trivia

Welcome friends to the first quiz of E-SAT- March 2012, this quiz will be on Cefi L Med Ref and will be open from 12th March 6pm onwards(Monday) to 18th March '2012(Sunday) till 11. 59pm. This quiz will be open for 7 full days including Sunday 18th March '2012. Wishing you all the best


Questions and Answers
  • 1. 
    Indication of CEFI L
    • A. 

      UTI

    • B. 

      LRTI

    • C. 

      URTI

    • D. 

      RTI

  • 2. 
    Conclusion of Comparative study of 2 dosage regimens of cefixime in the treatment of otorhinolaryngeal or bronchial infections 
    • A. 

      Efficacy of Cefixime 400mg OD is not equal to Cefixime 200 mg twice daily

    • B. 

      Cefixime 400mg OD is not recommended in LRTI

    • C. 

      Efficacy of cefixime 400 mg once daily is equal to cefixime 200mg twice daily

    • D. 

      Dosage of Levofloxacin is 500mg OD

  • 3. 
    Dosage of cefixime is clearly mentioned in which standard medical text books  
    • A. 

      Harrisons Internal Medicine

    • B. 

      Merck Manual & Martindale

    • C. 

      Goodman and Gillman

    • D. 

      Text book of Clinical Pharmacology

  • 4. 
    As per standard Text books Merck Manual and Martindale
    • A. 

      Cefixime has excellent coverage against Atypical bacteria and G+ve bacteria

    • B. 

      Levofloxacin has excellent coverage against G-ve bacteria

    • C. 

      Cefixime has excellent Gram negative activity while levofloxacin is very active against Gram positive and atypical bacteria.

    • D. 

      None of the above

  • 5. 
    Name the Journal which speaks about the benefits of combination.
    • A. 

      Journal of Antibacterials 1978

    • B. 

      Journal of Antibiotics 2001

    • C. 

      Journal of Antimicrobials 2011

    • D. 

      Journal of Antimicrobial Chemotherapy in year 2011.

  • 6. 
    What is the full form of BMC in  BMC infectious Disease
    • A. 

      Bio Med Central

    • B. 

      Bio Med Circle

    • C. 

      Bio Med Care

    • D. 

      Bio Med Center

  • 7. 
    BMC Infectious Disease 2011 endorses
    • A. 

      Beta Lactam with Nitoimidazole can be given as emperical First line therapy in LRTI

    • B. 

      Beta Lactam with Quinolone can be given as emperical First line therapy in LRTI

    • C. 

      Beta Lactam with Aminoglycosides can be given as emperical First line therapy in LRTI

    • D. 

      All of the above

  • 8. 
    Punch Line of CEFI L
    • A. 

      Super Coverage , Increase clinic outcome

    • B. 

      Superior coverage Improves Clinical Outcome

    • C. 

      Excellent activity to ensure success

    • D. 

      Superior coverage, Improves Patient Income

  • 9. 
    Dosage of CEFI L
    • A. 

      1 tablet OD for 3 days

    • B. 

      BID for a period of 5 days

    • C. 

      1 Tablet TID daily for 5days

    • D. 

      1 tablet once daily for a period of 7 days

  • 10. 
    Levofloxacin shows _______ susceptibility against S.pneumoniae
    • A. 

      99%

    • B. 

      97%

    • C. 

      95%

    • D. 

      93%